Biosensors International (SGX: B20)

B20 Technical Analysis

5

As on
4th Apr 2016 B20 Share Price closed @
0.83 and we RECOMMENDStrong Buy
for LONG-TERM with Stoploss of
0.77 &
Strong Buy for SHORT-TERM with Stoploss of
0.81
we also expect STOCK to react on Following IMPORTANT LEVELS.

Biosensors International Group, Ltd., an investment holding company, engages in the research and development, manufacture, assembly, marketing, distribution, and sale of medical devices for interventional cardiology and critical care procedures worldwide. It operates through three segments: Interventional Cardiology, Critical Care, and Licensing Revenue. The Interventional Cardiology segment supplies its proprietary drug-eluting stent products, coronary bare-metal stents, accompanying stent delivery balloon catheter systems, angioplasty balloons, and catheters under the BioMatrix Flex, BioMatrix NeoFlex, Axxess, BioFreedom, Gazelle, and Powerline brand names. The Critical Care segment supplies catheter systems and related accessories that are used in surgeries, and intensive care treatment and monitoring procedures. It offers its products under the ACCUTRANS, BIOTRANS, and BIOTRAY brand names. The Licensing Revenue segment engages in the licensing of its proprietary drug-eluting stent technology and intellectual property. The company was founded in 1990 and is headquartered in Singapore.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors or delays in the content,
or for any actions taken in reliance thereon.
Your use of this website constitutes acceptance of our Terms Of Service